After 1 and 2 weeks of treatment, the metabolic features in the AD-specific cerebral regions of Sco-induced and MCE-treated rats grew close to those of normal rats, while the metabolism of the Gal-treated group increased and became close to the metabolic aspects of the affected group. The gene discussed is GAL; the disease is Alzheimer disease.